# BLUEJET (BLUEJET) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/bluejet

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹575.55
- Change: +1.29%
- As of: 2026-09-18
- 1D return: +1.24%
- 5D return: -0.01%
- 1M return: -3.37%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, BLUEJET is trading at ₹575.25, with a technical stance that shows mixed signals across different timeframes. The daily timeframe indicates a weakening trend, with the price below key moving averages like the 20-day Exponential Moving Average (EMA) and 20-day Simple Moving Average (SMA), and the Supertrend indicator suggesting a bearish signal. This is further supported by a moderate upward anomaly on September 16, 2026, characterized by a wide intraday range and a positive return, despite a negative ADX value suggesting a lack of strong directional momentum.

In contrast, the weekly timeframe presents a more constructive picture, with the price trading above its 20-day and 50-day EMAs and SMAs, and the Supertrend indicator showing a bullish direction. The ADX on the weekly chart is higher at 37.23, indicating stronger trend presence. However, the monthly timeframe reverts to a bearish outlook, with the price below its 20-day EMA and SMA, and the Supertrend also indicating bearishness, though the ADX is relatively subdued at 22.72.

The stock is currently positioned near its nearest resistance level at ₹575.65, which is only 0.07% above the current price. Key support is observed around ₹569.45, approximately 1.01% below the current price. The stock has experienced a recent drawdown of -0.43% and has an annualized volatility of 51%. Active patterns include a Hammer formation on the weekly chart and a Doji on the monthly chart, both observed on September 18, 2026.

- Current price as of September 18, 2026: ₹575.25.
- Nearest resistance level: ₹575.65 (0.07% above current price).
- Nearest support level: ₹569.45 (1.01% below current price).
- Daily timeframe shows a bearish trend with price below key moving averages.
- Weekly timeframe shows a bullish trend with price above key moving averages and a Hammer pattern.
- Monthly timeframe indicates a bearish trend with price below key moving averages and a Doji pattern.

- Hammer
- Doji
- Harami
- Outside Bar

### News Context

Blue Jet Healthcare Limited has scheduled its 58th Annual General Meeting (AGM) for September 21, 2026, to be conducted virtually. Key agenda items include the adoption of financial statements for the fiscal year ending March 31, 2026, and the declaration of a final dividend of ₹1.20 per equity share. The meeting will also address the re-appointment of M/s. KKC & Associates LLP as statutory auditors for a second five-year term and the re-appointment of executive management, including Mr. Akshay Bansarilal Arora as Whole-Time Director and Executive Chairman and Mr. Shiven A. Arora as Managing Director, for five-year terms commencing April 13, 2027. Additionally, the company reported a reduction in greenhouse gas emissions for FY 2025-26 compared to the previous year, achieving zero Lost Time Injury Frequency Rate and zero fatalities. Approximately 90% of the company's turnover is derived from exports, and the Business Responsibility and Sustainability Report (BRSR) for FY 2025-26 has received reasonable assurance for its core indicators.

- Blue Jet Healthcare will hold its 58th AGM on September 21, 2026, via video conference.
- A final dividend of ₹1.20 per equity share for FY 2025-26 is proposed.
- The company reported a decrease in Scope 1 and Scope 2 greenhouse gas emissions to 32,138.47 tCO2e in FY 2025-26 from 34,885.47 tCO2e in FY 2024-25.
- Re-appointments of statutory auditors and key management personnel are on the AGM agenda.
- Approximately 90% of the company's revenue comes from exports.

- Blue Jet Healthcare Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- Blue Jet Healthcare Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 21, 2026 |SUBJECT: Shareholders meeting
- BLUE JET HEALTHCARE LIMITED has informed the Exchange about Notice of Shareholders Meeting for Annual General Meeting to be held on 21-Sep-2026 |SUBJECT: Notice Of Shareholders Meetings-XBRL
- Blue Jet Healthcare Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report for the FY 2025-26'. |SUBJECT: Updates
- AS ON DATE : 18-AUG-26

### What Changed

As of September 18, 2026, Blue Jet Healthcare's stock price has seen a modest increase, trading at ₹575.25 compared to its previous price of ₹565.0. The available evidence does not indicate any new filings or news events that have occurred recently. The company's profile on the NSE remains unchanged.

- Stock price on September 18, 2026: ₹575.25
- Previous stock price: ₹565.0
- No new filings or news reported as of September 18, 2026.
- Company listed on NSE.

### Official Filings

Blue Jet Healthcare Limited is preparing for its 58th Annual General Meeting (AGM) scheduled for September 21, 2026. This meeting will address several key items, including the adoption of audited financial statements for the fiscal year ended March 31, 2026, and the proposed declaration of a final dividend of ₹1.20 per equity share. The company has also announced plans for leadership transitions and auditor re-appointments. Mr. Akshay Bansarilal Arora is slated for re-appointment as Whole-Time Director and Executive Chairman, and Mr. Shiven A. Arora as Managing Director, both for five-year terms commencing April 13, 2027. Additionally, M/s. KKC & Associates LLP is proposed for re-appointment as Statutory Auditors for a second five-year term. The company has also published its Business Responsibility and Sustainability Report for FY 2025-26, noting a reduction in greenhouse gas emissions and maintaining a zero Lost Time Injury Frequency Rate. Approximately 90% of the company's turnover is derived from exports.

- The 58th Annual General Meeting is scheduled for September 21, 2026, to be held via video conferencing.
- A final dividend of ₹1.20 per equity share for the financial year ended March 31, 2026, has been recommended, with a record date of September 14, 2026.
- Proposed re-appointment of M/s. KKC & Associates LLP as Statutory Auditors for a second five-year term, effective September 21, 2026.
- Proposed re-appointment of Mr. Akshay Bansarilal Arora as Whole-Time Director and Executive Chairman, and Mr. Shiven A. Arora as Managing Director, for five-year terms starting April 13, 2027.
- The Business Responsibility and Sustainability Report for FY 2025-26 indicates a reduction in Scope 1 and Scope 2 greenhouse gas emissions to 32,138.47 tCO2e from 34,885.47 tCO2e in the prior fiscal year.

- Blue Jet Healthcare Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- Blue Jet Healthcare Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 21, 2026 |SUBJECT: Shareholders meeting
- BLUE JET HEALTHCARE LIMITED has informed the Exchange about Notice of Shareholders Meeting for Annual General Meeting to be held on 21-Sep-2026 |SUBJECT: Notice Of Shareholders Meetings-XBRL
- Blue Jet Healthcare Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report for the FY 2025-26'. |SUBJECT: Updates
- AS ON DATE : 18-AUG-26
- Blue Jet Healthcare Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- BLUE JET HEALTHCARE LIMITED has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA

### Fundamentals

Blue Jet Healthcare's recent financial performance shows a mixed trajectory. For the quarter ending June 2027 (Q1 FY27), the company reported Revenue from Operations of ₹293.11 crore, an increase from ₹192.41 crore in Q3 FY26 and ₹234.67 crore in Q4 FY26. Profit Before Tax followed a similar upward trend, reaching ₹105.95 crore in Q1 FY27, compared to ₹53.78 crore in Q3 FY26 and ₹87.15 crore in Q4 FY26. The net profit for Q1 FY27 was ₹78.26 crore. The Operating Profit Margin (OPM) for Q1 FY27 was 33%, down from 41% in Q4 FY26 but up from 30% in Q3 FY26.

Looking at the longer-term historical data, the company's Sales showed a compounded growth of 10% over 3 years and 14% over 5 years, but a decline of -28% on a Trailing Twelve Months (TTM) basis. Similarly, Compounded Profit Growth was 15% over 3 years and 11% over 5 years, but a significant -34% on a TTM basis. Return on Equity (ROE) stood at 19% last year, with a 3-year CAGR of 24% and a 5-year CAGR of 26%.

Financially, the company has significantly reduced its borrowings from ₹74.0 crore in March 2020 to ₹3.0 crore in March 2024, with a projected increase to ₹21.0 crore by March 2025 and ₹44.0 crore by March 2026. Equity Capital remained stable at ₹35.0 crore from March 2022 to March 2026. Investments have fluctuated, standing at ₹250.0 crore in March 2024 and projected to be ₹187.0 crore in March 2025 and ₹252.0 crore in March 2026. Cash flow from operations has been strong, with ₹241.0 crore in March 2024, but Free Cash Flow has seen a decline, turning negative at -₹34.0 crore in the projection for March 2025, before recovering to ₹115.0 crore in March 2026. The Cash Conversion Cycle has been increasing, reaching 206 days in March 2024 and projected to be 262 days in March 2025.

- For Q1 FY27, Revenue from Operations was ₹293.11 crore, Profit Before Tax was ₹105.95 crore, and Net Profit was ₹78.26 crore.
- The Operating Profit Margin (OPM) was 33% in Q1 FY27.
- TTM Sales growth was -28% and TTM Profit growth was -34%, contrasting with 3-year and 5-year compounded growth rates of 10% and 14% for sales, and 15% and 11% for profit, respectively.
- Borrowings have decreased significantly from ₹74.0 crore in March 2020 to ₹3.0 crore in March 2024, with projections to rise to ₹44.0 crore by March 2026.
- Free Cash Flow was negative at -₹34.0 crore in the March 2025 projection, after being ₹68.0 crore in March 2024.

### Bull Case

Blue Jet Healthcare's financial performance shows a notable increase in operating cash flow, moving from ₹46.0 crore in March 2025 to ₹334.0 crore in March 2026. This improvement is further reflected in a positive shift in free cash flow, which is projected to increase from a negative ₹34.0 crore in March 2025 to a positive ₹115.0 crore in March 2026. The company's reserves have also grown, from ₹1098.0 crore in March 2025 to ₹1325.0 crore in March 2026, indicating an increase in retained earnings. On a longer-term basis, the company has demonstrated compounded sales growth of 14% over 5 years, though recent performance shows a decline. Technically, the weekly trend indicates a bullish Supertrend direction as of September 18, 2026, with the price trading above the Supertrend level of ₹448.4.

- Operating cash flow increased from ₹46.0 crore (Mar 2025) to ₹334.0 crore (Mar 2026).
- Free Cash Flow is projected to turn positive, from ₹-34.0 crore (Mar 2025) to ₹115.0 crore (Mar 2026).
- Reserves grew from ₹1098.0 crore (Mar 2025) to ₹1325.0 crore (Mar 2026).
- The 5-year compounded sales growth was 14%.

### Bear Case

Blue Jet Healthcare's recent financial performance shows a notable decline in sales and profits on a trailing twelve months (TTM) basis, with sales down 28% and profits down 34%. This contrasts with a 5-year compounded sales growth of 14% and profit growth of 11%, suggesting a recent operational slowdown. The company's balance sheet indicates a significant increase in borrowings from ₹21.0 crore in March 2025 to ₹44.0 crore in March 2026, alongside a substantial rise in Capital Work-in-Progress (CWIP) from ₹89.0 crore to ₹301.0 crore over the same period. This expansion in CWIP, coupled with increased borrowing, may indicate significant ongoing capital expenditure or investment, which could strain cash flows in the short term, although free cash flow is projected to turn positive in March 2026. Technical indicators suggest a bearish trend on daily and monthly timeframes, with the Supertrend indicator pointing downwards and the 20-day Exponential Moving Average (EMA) showing a negative slope.

- TTM sales growth is -28% and TTM profit growth is -34%, compared to 5-year compounded growth rates of 14% and 11% respectively.
- Borrowings are projected to increase from ₹21.0 crore in Mar 2025 to ₹44.0 crore in Mar 2026.
- Capital Work-in-Progress (CWIP) is expected to rise significantly from ₹89.0 crore in Mar 2025 to ₹301.0 crore in Mar 2026.
- Daily and monthly technical trends indicate a bearish Supertrend direction as of September 18, 2026.

### FAQs

**What is the company's projected financial performance for the fiscal years ending March 2025 and March 2026?**

For the fiscal year ending March 2025, Blue Jet Healthcare's projected total assets are ₹1,418.0, with total liabilities also at ₹1,418.0. Reserves are expected to be ₹1,098.0. For the fiscal year ending March 2026, total assets are projected to be ₹1,641.0, with total liabilities at ₹1,641.0 and reserves at ₹1,325.0. Cash flow from operating activities is projected to increase from ₹46.0 in March 2025 to ₹334.0 in March 2026. Free cash flow is expected to move from a negative ₹34.0 in March 2025 to a positive ₹115.0 in March 2026.

**What are the key upcoming events for Blue Jet Healthcare?**

Blue Jet Healthcare will hold its 58th Annual General Meeting on September 21, 2026, conducted virtually via video conferencing. The agenda includes adopting financial statements for the year ended March 31, 2026, declaring a dividend of ₹1.20 per equity share, and considering the re-appointment of statutory auditors and key management personnel. The record date for the dividend is September 14, 2026.

**How has Blue Jet Healthcare's sales and profit growth trended recently?**

Over the last 5 years, Blue Jet Healthcare has shown a compounded sales growth of 14% and a compounded profit growth of 11%. However, for the Trailing Twelve Months (TTM) period, sales growth has declined by 28%, and profit growth has decreased by 34%.

**What is the company's current technical trading position based on recent data?**

As of September 18, 2026, the daily trend indicators suggest a bearish Supertrend at 608.2, with the closing price at ₹575.25. The weekly trend, however, shows a bullish Supertrend at 448.4. The stock has experienced a 1-year return of -16% and a year-to-date return of 9%.

**What are the company's sustainability efforts as reported for FY 2025-26?**

For the fiscal year 2025-26, Blue Jet Healthcare reported a reduction in Scope 1 and Scope 2 greenhouse gas emissions to 32,138.47 tCO2e from 34,885.47 tCO2e in the previous fiscal year. The company maintained a zero Lost Time Injury Frequency Rate and zero fatalities. Approximately 90% of the company's turnover is derived from exports.

- Blue Jet Healthcare Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- Blue Jet Healthcare Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 21, 2026 |SUBJECT: Shareholders meeting
- BLUE JET HEALTHCARE LIMITED has informed the Exchange about Notice of Shareholders Meeting for Annual General Meeting to be held on 21-Sep-2026 |SUBJECT: Notice Of Shareholders Meetings-XBRL
- Blue Jet Healthcare Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report for the FY 2025-26'. |SUBJECT: Updates
- AS ON DATE : 18-AUG-26
## Technical analytics

- As of: 2026-09-18
- Daily trend: Weak Downtrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹569.45
- Risk regime: Higher Price Risk

### Support levels
- 567.0250000000001
- 557.4125
- 543.7

### Resistance levels
- 582.75
- 599.9
- 613.0375

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +1.24% |
| return_10 | -0.65% |
| return_1m | -5.27% |
| return_1y | -15.81% |
| return_20 | -3.37% |
| return_3m | +12.60% |
| return_5 | -0.01% |
| return_6m | +50.08% |
| return_since_start | -0.38% |
| return_ytd | +8.74% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | high_risk |
| label | Higher price risk |
| summary | Recent drawdown or price variability is materially high and may lead to larger short-term outcomes. |
| maximum_drawdown | -67.61% |
| annualized_volatility | +50.91% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Sequential Recovery Leaves Year-on-Year Gap

Blue Jet Healthcare reported revenue of ₹293.11 crore and net profit of ₹78.26 crore for the first quarter of FY2026‑27, ended 30 June 2026. While both figures marked a sharp improvement from the lows of the previous fiscal year, they remained well below the levels recorded in the same quarter a year ago. The quarter’s performance highlights a recovery in business activity from the mid‑year trough, but the company has not yet returned to its prior‑year peak.

## Revenue Trajectory

Revenue for the quarter stood at ₹293.11 crore. This was a 24.9% increase from the ₹234.67 crore reported in the fourth quarter of FY2025‑26, and it followed even lower revenue in the second and third quarters of that year. The sequential rise shows a meaningful pickup from the weaker second half of the previous fiscal year.

Compared with the same quarter a year ago, however, revenue fell 17.4% from ₹354.76 crore in Q1 FY2025‑26. The current quarter’s revenue therefore sits between the prior‑year high and the mid‑year troughs of ₹165.48 crore (Q2) and ₹192.41 crore (Q3). Over the five‑quarter period, revenue has fluctuated considerably, with the latest figure representing a partial recovery rather than a return to the earlier peak.

## Profitability and Margins

Profit before tax (PBT) was ₹105.95 crore, up 21.6% from ₹87.15 crore in the previous quarter. Other income of ₹15.24 crore contributed to pre‑tax profit. The ratio of PBT to revenue (which includes other income) rose to 36.1% from 34.6% in Q1 FY2025‑26.

Net profit for the quarter was ₹78.26 crore, yielding a net profit margin of 26.7% compared with 25.7% a year earlier. The improvement in both ratios indicates that the company generated more profit per rupee of revenue, even as total revenue declined.

## Expense Breakdown

Cost of materials consumed was the largest expense at ₹178.88 crore, representing 61% of revenue. Employee benefit expenses amounted to ₹20.12 crore.

Other expenses fell 11.5% sequentially to ₹37.81 crore from ₹42.72 crore in Q4 FY2025‑26. This decline, alongside higher revenue, supported the rise in pre‑tax profit. On a year‑on‑year basis, other expenses increased from ₹33.44 crore in Q1 FY2025‑26 to ₹37.81 crore.

Finance costs remained low at ₹0.66 crore, little changed from the previous quarter and well below the ₹4.63 crore recorded in Q2 of the prior fiscal year. Depreciation and amortisation expenses were ₹6.71 crore, or 2.3% of revenue.

## Bottom Line and Earnings Per Share

Net profit of ₹78.26 crore was 21.6% higher than the ₹64.34 crore reported in the preceding quarter, but 14.2% lower than the ₹91.17 crore earned in Q1 FY2025‑26. Basic and diluted earnings per share followed the same pattern, rising to ₹4.51 from ₹3.71 sequentially, while declining from ₹5.26 a year earlier.

The tax expense for the quarter was ₹27.68 crore, resulting in an effective tax rate of 26.1% on pre‑tax profit. This was broadly in line with the 25.8% rate recorded in the same quarter last year.

## Key Takeaway

Blue Jet Healthcare’s first quarter delivered a strong sequential recovery from the lows of the previous fiscal year, with revenue and net profit each rising more than 20% from the prior quarter. However, both the top and bottom lines remained significantly below the year‑ago quarter, with revenue down 17% and net profit down 14%. Profit margins improved year‑on‑year, showing that the company earned more profit per rupee of revenue despite the lower sales volume. The quarter reflects a business that is recovering from a mid‑year trough but has not yet regained its prior‑year scale.

### Ratios

## Official filings

- 2026-08-19 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_19082026104031_SE_Upload.pdf)
- 2026-08-18 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_18082026134349_SE_Intimation_Notice_of_AGM_F.pdf)
- 2026-08-18 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_21086_WebXMLFile_20260818_134937698.xml)
- 2026-08-18 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_18082026134827_SE_Intimation_BRSR_F.pdf)
- 2026-08-17 — Annual Report: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/annual_reports/AR_30401_BLUEJET_2025_2026_A_7366578_18082026134049.pdf)
- 2026-08-12 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_12082026122455_Stock_Exchange_Upload.pdf)
- 2026-08-07 — Generic Announcement: Blue Jet Healthcare Limited held an earnings call on August 3, 2026, to discuss financial results for the quarter ended June 30, 2026. The company reported revenue of INR293 crores and EBITDA of INR98 crores, with improvements driven by the PI vertical. Key strategic initiatives include progress on the Vizag project, with an investment of approximately INR1,000 crores over three years, and the Hyderabad R&D center expected to become operational in August 2026. The company also noted INR210 crores invested in the Mahad backward integration project for contrast media intermediates, with an additional INR40 crores committed. — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_07082026103420_SEUploadTranscript.pdf)
- 2026-08-04 — Generic Announcement: Blue Jet Healthcare Limited published its unaudited standalone financial results for the quarter ended June 30, 2026, on August 4, 2026. The results were advertised in the Financial Express and Navshakti newspapers. The full financial results are available on the BSE website and the company's investor relations portal. — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_04082026115159_Stock_Exchange_Upload_Newspaper.pdf)
- 2026-08-03 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_21086_WebXMLFile_20260803_132821291.xml)
- 2026-08-03 — Generic Announcement: The Board of Directors of Blue Jet Healthcare Limited approved the unaudited standalone financial results for the quarter ended June 30, 2026. They also approved the re-appointment of Mr. Akshay B Arora as Whole Time Director and Executive Chairman, and Mr. Shiven Akshay Arora as Managing Director, both for five-year terms effective April 13, 2027. M/s KKC & Associates LLP was approved for re-appointment as Statutory Auditors for a second five-year term. A record date of September 14, 2026, was set for a dividend of Rs. 1.2 per equity share, and the 58th Annual General Meeting is scheduled for September 21, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_03082026124424_FinalUpload.pdf)
- 2026-08-03 — Generic Announcement: Blue Jet Healthcare Limited announced its financial results for the first quarter ended June 30, 2026, reporting revenue of ₹2,931 million, EBITDA of ₹981 million (33% margin), and PAT of ₹783 million (27% margin). This represents a 25% increase in revenue quarter-over-quarter compared to Q4 FY26, but a 17% decrease year-over-year compared to Q1 FY26. The company also completed a Qualified Institutional Placement (QIP) raising ₹8,000 million by allotting equity shares at ₹506 each. — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_03082026152028_SEUpload_investorpresentation.pdf)
- 2026-08-03 — Generic Announcement: The Board of Directors of Blue Jet Healthcare Limited approved the unaudited standalone financial results for the quarter ended June 30, 2026. They also approved the re-appointment of Mr. Akshay B Arora as Whole Time Director and Executive Chairman, and Mr. Shiven Akshay Arora as Managing Director, both for five-year terms effective April 13, 2027. M/s KKC & Associates LLP was approved for re-appointment as Statutory Auditors for a second five-year term. A record date of September 14, 2026, was set for a dividend of Rs. 1.2 per equity share, and the 58th Annual General Meeting is scheduled for September 21, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_03082026125021_FinalUpload.pdf)
- 2026-08-03 — Generic Announcement: The Board of Directors of Blue Jet Healthcare Limited approved the unaudited standalone financial results for the quarter ended June 30, 2026. They also approved the re-appointment of Mr. Akshay B Arora as Whole Time Director and Executive Chairman, and Mr. Shiven Akshay Arora as Managing Director, both for five-year terms effective April 13, 2027. M/s KKC & Associates LLP was approved for re-appointment as Statutory Auditors for a second five-year term. A record date of September 14, 2026, was set for a dividend of Rs. 1.2 per equity share, and the 58th Annual General Meeting is scheduled for September 21, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_03082026124654_FinalUpload.pdf)
- 2026-08-03 — Generic Announcement: The Board of Directors of Blue Jet Healthcare Limited approved the unaudited standalone financial results for the quarter ended June 30, 2026. They also approved the re-appointment of Mr. Akshay B Arora as Whole Time Director and Executive Chairman, and Mr. Shiven Akshay Arora as Managing Director, both for five-year terms effective April 13, 2027. M/s KKC & Associates LLP was approved for re-appointment as Statutory Auditors for a second five-year term. A record date of September 14, 2026, was set for a dividend of Rs. 1.2 per equity share, and the 58th Annual General Meeting is scheduled for September 21, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_03082026124851_FinalUpload.pdf)
- 2026-08-03 — Generic Announcement: Blue Jet Healthcare Limited has submitted an audio recording of its earnings conference call held on August 3, 2026, to discuss financial results for the quarter ended June 30, 2026. The recording is available on the company's website. — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_03082026204330_Intimation_Audio_recording_FY.pdf)
- 2026-07-28 — Generic Announcement: Blue Jet Healthcare Limited will host an analyst and investor call on August 3, 2026, at 5:30 PM IST to discuss the unaudited standalone financial results for the quarter ended June 30, 2026. The call will include management representatives such as the Managing Director, COO, CFO, and Deputy CFO. — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_28072026151810_SE_upload_call_intimation.pdf)
- 2026-07-28 — Official Filing: Blue Jet Healthcare Limited will hold a board meeting on August 3, 2026, to consider unaudited standalone financial results for the quarter ended June 2026. The trading window for the company's securities will be closed from June 25, 2026, and will reopen on August 8, 2026.
- 2026-07-27 — Shareholding Disclosure: Akshay Bansarilal Arora, along with persons acting in concert including Shiven Akshay Arora and Archana Akshay Arora, declared that no encumbrance on their equity holdings occurred during the financial year ended March 31, 2026. The declaration, submitted on April 7, 2026, covers a total of 138,445,726 equity shares representing 79.81% of the total share capital. — [Official attachment](https://nsearchives.nseindia.com/corporate/team_bbodade_14072026182530_12052026192256_BLUEJET.pdf)
- 2026-07-20 — Press Release: Blue Jet Healthcare Limited was awarded a Silver Medal by EcoVadis on July 20, 2026, for its sustainability management practices in Environment, Labor and Human Rights, Ethics, and Sustainable Procurement. The company achieved an EcoVadis Sustainability Score of 77 out of 100, ranking it among the top 15% of companies globally evaluated by EcoVadis. — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_20072026145656_SEIntimation_EcoVadis_F.pdf)
- 2026-07-14 — Generic Announcement: Blue Jet Healthcare Limited received a compliance certificate from MUFG Intime India Private Limited for the quarter ended June 30, 2026. The certificate confirms that Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, is not applicable to the company as all its shares are held in demat form and no rematerialization requests were received during the quarter. — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_14072026104435_Reg_74_5__Upload.pdf)
- 2026-07-09 — Generic Announcement: Blue Jet Healthcare Limited closed its Qualified Institutions Placement (QIP) on July 9, 2026, allocating 15,810,276 equity shares at ₹506.00 per share. The issue price represents a discount of ₹25.70 per share from the floor price of ₹531.70. The company's Investment and Finance Committee approved the closure, allocation, and placement document during a meeting held on the same date. — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_09072026200129_SE_Announcement_Issue_close_Final_sign.pdf)
- 2026-07-09 — Generic Announcement: Blue Jet Healthcare Limited approved the issue and allotment of 15,810,276 equity shares at ₹506.00 per share on July 9, 2026, raising ₹8,000 million through a Qualified Institutions Placement. This issuance increased the company's paid-up equity share capital to ₹378,551,402, comprising 189,275,701 equity shares. The placement was open from July 6, 2026, to July 9, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_09072026224520_SE_Announcement__Allotment_Final.pdf)
- 2026-07-06 — Generic Announcement: Blue Jet Healthcare Limited's Investment and Finance Committee approved a qualified institutions placement on July 6, 2026, setting the floor price at ₹ 531.70 per equity share. The company also authorized the opening of the issue on the same date, with the potential for a discount of up to 5% on the floor price. This action follows approvals from the board of directors on May 25, 2026, and shareholders on June 17, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_06072026194522_SE_Announcement__1__signed.pdf)
- 2026-07-06 — Generic Announcement: Blue Jet Healthcare Limited has submitted its audited standalone financial statements for the fiscal year ending March 31, 2026. The Board of Directors approved these statements on May 25, 2026. The financial statements, including the balance sheet, profit and loss statement, statement of changes in equity, and statement of cash flows, have been prepared in accordance with Indian Accounting Standards. The company's revenue from operations for the year was ₹904.73 million, with a profit after tax of ₹247.16 million. — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_06072026145336_Signed_Financials_2026.pdf)
- 2026-06-25 — Generic Announcement: Blue Jet Healthcare Limited will close its trading window for designated persons and their immediate relatives from July 1, 2026, until 48 hours after the declaration of its first quarter unaudited financial results for the period ending June 30, 2026. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_25062026132037_Trading_Window_Closure.pdf)

## News and market events

- 2026-09-11 — Mint: **Dividend stocks alert! Last chance to qualify- Kalyan Jewellers, Aarti Industries, Blue Jet, Bajaj Healthcare, more** — Dividend stocks including Kalyan Jewellers, Aarti Industries, and 38 more, are poised to attract investor interest on Friday, September 11. These companies have set record dates for dividend payouts on September 12 and 14. — [Source](https://www.livemint.com/market/stock-market-news/dividend-stocks-alert-last-chance-to-qualify-kalyan-jewellers-aarti-industries-blue-jet-bajaj-healthcare-more-11789098026451.html)
- 2026-09-08 — MONEYCONTROL: **Axis AMC PMS fund dumps DMart on q-comm squeeze, exits REC over state discom credit risks** — Axis AMC, PMS, Alternates, Axis brokerage. portfolio management — [Source](https://www.moneycontrol.com/news/business/markets/axis-amc-pms-fund-dumps-dmart-on-q-comm-squeeze-exits-rec-over-state-discom-credit-risks-14024970.html)
- 2026-08-04 — MONEYCONTROL: **Buy Blue Jet Healthcare; target of Rs 680: ICICI Securities** — ICICI Securities, Blue Jet Healthcare, buy, Recommendations — [Source](https://www.moneycontrol.com/news/business/stocks/buy-blue-jet-healthcare-target-of-rs-680-icici-securities-13993613.html)
- 2026-08-03 — The Hindu: **Sensex today | Stock Market Live: Sensex up 600 pts, Nifty holds 24,500; IndiGo leads gainers** — Sensex, Nifty, Stock Price Live Updates: The fresh week began on a positive note for Indian stocks, thanks to softer crude oil prices and stable global markets. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-3rd-august-2026/article71298312.ece)
- 2026-08-03 — CNBC-TV18: **Blue Jet Healthcare Q1 Results: Shares fall 5% after profit, revenue decline from last year** — Blue Jet Healthcare's revenue from operations fell 17.4% year-on-year to ₹293 crore, down from ₹355 crore a year earlier. — [Source](https://www.cnbctv18.com/market/blue-jet-healthcare-q1-results-shares-fall-after-profit-revenue-decline-from-last-year-19960348.htm)
- 2026-08-03 — CNBC-TV18: **Q1 Results LIVE Updates: Blue Jet Healthcare shares fall over 5%; One Mobikwik up over 6%** — Q1 Results LIVE Updates: SBI Funds Management, Ather Energy, Inox India, IREDA, DOMS Industries, DLF, Escorts Kubota, CAMS, NOCIL, Nazara Tech, PNC Infra, Torrent Power, UPL, Restaurant Brands Asia, PNC Infra, KIMS, KEI Industries, Jindal Stainless, Ethos, GSK Pharma, Bluejet Healthcare, Kansai Nerolac, JM Financial, Kalpataru, Dhanuka Agritech, Texmaco Rail, are among the companies reporting their earnings today. Results reactions will come from stocks like ITC, Maruti Suzuki, Muthoot Finance, Dixon tech, and many others. Watch this space for all the LIVE Q1 results updates. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-maruti-sbi-mf-upl-dlf-ireda-ioc-dixon-persistent-muthoot-cams-escorts-ather-abb-divis-share-price-liveblog-19959998.htm)
- 2026-08-03 — CNBC-TV18: **Sensex Today | Stock Market Live Updates: Nifty up over 200 points; IndiGo, Shriram Fin top gainers** — Sensex Today | Stock Market Live Updates: We are at the halfway mark of the day's trade, and the markets are trading on a strong footing, holding onto the gains. The Nifty is up over 200 points, rising above 24,600. The Nifty Bank is also higher, jumping over 530 points, rising to 57,600. ITC, Shriram Fin and IndiGo are top gainers. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-oil-fcnr-rupee-itc-maruti-autos-ioc-divis-zee-stl-banks-share-price-liveblog-19959976.htm)
- 2026-08-03 — MONEYCONTROL: **Trade Spotlight: How should you trade Hero MotoCorp, Anant Raj, Anthem Biosciences, KEI Industries, Escorts, BLS E-Services, and others on August 3?** — Trade Spotlight, Buy Ideas,Top Buy Ideas,Top Picks,Stock Picks,Top Stock Picks,Share Tips,Share Market Tips,Stock Tips,Stock Market Tips,BLS E-Services,Hero MotoCorp,Jio Financial Services,Anant Raj,Anthem Biosciences,Blue Jet Healthcare,Shipping Corporation of India,KEI Industries,Escorts Kubota — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-hero-motocorp-anant-raj-anthem-biosciences-kei-industries-escorts-bls-e-services-and-others-on-august-3-13991407.html)

## Business profile

**Strategic vision:** Manufactures and supplies pharmaceutical and healthcare ingredients globally.

### Business segments
- **Contrast Media Intermediates:** Develops and manufactures high-purity contrast media intermediates used by pharmaceutical and diagnostic imaging companies worldwide, including intermediates for iodine-based and gadolinium-based contrast agents.
- **Artificial Sweeteners:** Manufactures Saccharin Sodium and Insoluble Saccharin for healthcare, pharmaceuticals, animal feed, food, and beverages, complying with major pharmacopoeial standards.
- **Protected Amino Acids & Derivatives and CDMO Services:** Offers protected amino acids, derivatives, and CDMO services for pharmaceutical intermediates and APIs, covering process development to commercialization for NCEs, intermediates, and APIs.

### Competitive strengths
- Specialization in niche chemical segments
- Extensive manufacturing experience in specific product lines
- Backward integration and indigenous sourcing of raw materials
- cGMP compliant facilities and robust regulatory support for CDMO services

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/bluejet
Markdown representation: https://faxioms.com/stocks/bluejet?render=md